Drugs / Beta Erythropoietin
Beta Erythropoietin
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00495547 | Feb 2009 → Jun 2011 | myelodysplastic syndrome | PETHEMA Foundation | Terminated | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT03408639 | Jun 2016 → Jul 2017 | aregenerative anemia | Cinnagen | Completed | No outcome recorded |
| Phase 3 | NCT01066351 | Jan 2010 → Mar 2011 | acute kidney injury | Thammasat University | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | beta erythropoietin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01066351 ↗ |
| Known as | CinnaPoietin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03408639 ↗ |
| Known as | epoetin beta | “This phase III study aimed to compare the efficacy and safety of CinnaPoietin® (epoetin beta, CinnaGen) with Eprex® (epoetin alfa, Janssen Cilag) in the treatment of anemia in...” PMID 30253403 ↗ Sep 2018 |
| Known as | Recormon | “The patients were assigned to receive beta erythropoietin (Recormon) dose 200 unit/kg at 3 day before cardiac surgery and 100 unit/kg in the morning before cardiac surgery.” NCT01066351 ↗ |
| Route | Intravenous | “One hundred patients randomly received either 200 U/kg of rHuEPO (n = 50) or saline (n = 50) intravenously three days before operation, and rHuEPO 100 U/kg or saline at operation time.” PMID 23829828 ↗ Jul 2013 |